• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
PCK
Click for more information
0.00% 2.8¢

PAINCHEK LTD - Announcements

Market Cap $50.71M  ! watchlist Created with Sketch. Add to my watchlist

PainChek Ltd is an Australia-based company, which develops pain assessment technologies.... PainChek Ltd is an Australia-based company, which develops pain assessment technologies. The Company's principal activities are development and commercialization of mobile medical device applications that provide pain assessment for individuals that are unable to communicate with their carers. The Company's PainChek Universal is a complete point-of-care solution that combines the existing PainChek Application with the numerical rating scale (NRS). PainChek Application uses artificial intelligence and facial recognition to detect pain in those who cannot self-report. This gives a voice to those who cannot verbalize pain, whilst also driving objectivity and consistency in all assessments. For those who can self-report, PainChek Universal also includes access to the NRS, a standard used to document pain levels amongst these individuals. PainChek Universal also supports pain assessment using both tools at the point of care, for those people whose ability to communicate fluctuates.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
PCK Company Presentation12/03/19
PCK Appendix 3B & Cleansing Notice01/03/19
PCK Half Yearly Report and AccountsPRICE SENSITIVE27/02/19
PCK Response to ASX Price QueryPRICE SENSITIVE13/02/19
PCK Quarterly UpdatePRICE SENSITIVE29/01/19
PCK Appendix 4C - quarterlyPRICE SENSITIVE29/01/19
PCK PainChek, Allity & Ward drive Personalised Pain Management16/01/19
PCK PainChek fast tracking UK commercialisation with trade award10/12/18
PCK Results of Meeting20/11/18
PCK Receipt of R&D Tax Incentive15/11/18
PCK PainChek launches professional carers online training course14/11/18
PCK PainChek Shared Care Program Changes Home Pain Management31/10/18
PCK Appendix 3B19/10/18
PCK Notice of Annual General Meeting/Proxy Form17/10/18
PCK Appendix 4G and Corporate Governance Statement17/10/18
PCK Annual Report to shareholders17/10/18
PCK Company Presentation16/10/18
PCK Quarterly UpdatePRICE SENSITIVE15/10/18
PCK Appendix 4C - quarterlyPRICE SENSITIVE15/10/18
PCK Additional Information on Share Escrow Release12/10/18
PCK Agreement with Leecare SolutionsPRICE SENSITIVE03/10/18
PCK Uptake of new PainChek App drives better quality aged care28/09/18
PCK Release of Securities from Escrow26/09/18
PCK Appendix 3B and Cleansing Notice13/09/18
PCK Company Presentation11/09/18
PCK Allity Aged Care partners with PainChekPRICE SENSITIVE10/09/18
PCK Full Year Statutory Accounts27/08/18
PCK Preliminary Final ReportPRICE SENSITIVE27/08/18
PCK Appendix 3B13/08/18
PCK Investor UpdatePRICE SENSITIVE31/07/18
PCK Appendix 4C - quarterlyPRICE SENSITIVE31/07/18
PCK National roll out with DSA follows successful pilotPRICE SENSITIVE14/06/18 download Created with Sketch. 289.82KB
PCK New publication confirms accuracy of PainChek(R)PRICE SENSITIVE07/06/18 download Created with Sketch. 297.6KB
PCK Dr Jennifer Abbey joins PainChek Ltd clinical advisory board04/06/18 download Created with Sketch. 272.49KB
PCK Investor Presentation17/05/18
PCK PainChek receives FDA regulatory guidancePRICE SENSITIVE09/05/18
PCK Quarterly Update and Appendix 4CPRICE SENSITIVE24/04/18
PCK Appendix 3B and Cleansing Notice13/04/18
PCK Appendix 3B and Cleansing Notice11/04/18
PCK PainChek DTA training and education video06/04/18
PCK Appendix 3B and Cleansing Notice04/04/18
PCK Agreement signed with leading software system providerPRICE SENSITIVE27/03/18
PCK PainChek Education and Training Presentation26/03/18
PCK Commentary on Half Year Report23/02/18
PCK Half Year Report and Financial StatementsPRICE SENSITIVE23/02/18
PCK Quarterly Update and Appendix 4CPRICE SENSITIVE30/01/18
PCK PainChek App Android version now in beta testingPRICE SENSITIVE30/01/18
PCK Appendix 3B29/01/18
PCK New Peer reviewed published studyPRICE SENSITIVE29/01/18
PCK PainChek Head of Business Development ANZ Appointment22/01/18
PCK Change of Company Name to PainChek Ltd17/01/18
PCK Certificate of Registration on Change of Name17/01/18
PCK Results of Meeting17/01/18
PCK Appendix 3B and Cleansing Notice21/12/17
PCK Company name change to PainChek Ltd15/12/17
PCK Notice of General Meeting/Proxy Form15/12/17
PCK Appendix 3B and Cleansing Notice13/12/17
PCK 2nd peer-review confirms excellent performance of PainChekPRICE SENSITIVE13/12/17
PCK Results of Meeting21/11/17
PCK AGM Presentation21/11/17
PCK PainChek Childrens App Commercialization Timelines on Track15/11/17
PCK ePAT and PainChek continue to achieve commercial milestonesPRICE SENSITIVE08/11/17
PCK Quarterly Update and Appendix 4CPRICE SENSITIVE31/10/17
PCK Appendix 3B and Cleansing Notice25/10/17
PCK Appendix 3B and Cleansing Notice20/10/17
PCK Notice of Annual General Meeting/Proxy Form13/10/17
PCK Appendix 4G and Corporate Governance Statement12/10/17
PCK Annual Report to shareholders12/10/17
PCK PainChek trademark and branding supports commercialisation10/10/17
PCK ePAT accelerates commercialisation at Alzheimers Conference26/09/17
PCK Cleansing Notice20/09/17
PCK Appendix 3B20/09/17
PCK Release of Securities from Escrow18/09/17
PCK Placement to raise $3.75 millionPRICE SENSITIVE18/09/17
PCK Trading HaltPRICE SENSITIVE14/09/17
PCK Appendix 3B08/09/17
PCK Allotment of Deferred Consideration Shares08/09/17
PCK Core strategic agreement with Dementia Support AustraliaPRICE SENSITIVE07/09/17
PCK Full Year Statutory Accounts29/08/17
PCK Preliminary Final ReportPRICE SENSITIVE29/08/17
PCK ePAT Clinical Study Published in Alzheimer's Disease JournalPRICE SENSITIVE15/08/17
PCK Response to ASX Price QueryPRICE SENSITIVE14/08/17
PCK Appendix 3B07/08/17
PCK Quarterly Update and Appendix 4CPRICE SENSITIVE31/07/17
PCK nViso agrees perpetual global license, takes strategic stakePRICE SENSITIVE24/07/17
PCK Response to ASX queryPRICE SENSITIVE24/07/17
PCK Appendix 3B24/07/17
PCK Investor Presentation19/07/17
PCK ePAT Pain Assessment App Secures Regulatory ClearancePRICE SENSITIVE19/07/17
PCK New Study Validates Face Recognition App in Pain DetectionPRICE SENSITIVE04/07/17
PCK Investor Presentation21/06/17
PCK Appendix 3B11/05/17
PCK Third Quarter Report FY 2016/1728/04/17
PCK Appendix 4C - quarterlyPRICE SENSITIVE28/04/17
PCK 1st version iOS App Introduced at Pain Society Conference11/04/17
PCK Appendix 3B05/04/17
PCK Appointment of Chief Technology Officer03/04/17
PCK Expiry of listed options31/03/17
PCK Launch of IBM Case StudyPRICE SENSITIVE15/03/17
PCK Appendix 3B13/03/17
PCK Company Presentation
12/03/19
PCK Appendix 3B & Cleansing Notice
01/03/19
PCK Half Yearly Report and Accounts
27/02/19PRICE SENSITIVE
PCK Response to ASX Price Query
13/02/19PRICE SENSITIVE
PCK Quarterly Update
29/01/19PRICE SENSITIVE
PCK Appendix 4C - quarterly
29/01/19PRICE SENSITIVE
PCK PainChek, Allity & Ward drive Personalised Pain Management
16/01/19
PCK PainChek fast tracking UK commercialisation with trade award
10/12/18
PCK Results of Meeting
20/11/18
PCK Receipt of R&D Tax Incentive
15/11/18
PCK PainChek launches professional carers online training course
14/11/18
PCK PainChek Shared Care Program Changes Home Pain Management
31/10/18
PCK Appendix 3B
19/10/18
PCK Notice of Annual General Meeting/Proxy Form
17/10/18
PCK Appendix 4G and Corporate Governance Statement
17/10/18
PCK Annual Report to shareholders
17/10/18
PCK Company Presentation
16/10/18
PCK Quarterly Update
15/10/18PRICE SENSITIVE
PCK Appendix 4C - quarterly
15/10/18PRICE SENSITIVE
PCK Additional Information on Share Escrow Release
12/10/18
PCK Agreement with Leecare Solutions
03/10/18PRICE SENSITIVE
PCK Uptake of new PainChek App drives better quality aged care
28/09/18
PCK Release of Securities from Escrow
26/09/18
PCK Appendix 3B and Cleansing Notice
13/09/18
PCK Company Presentation
11/09/18
PCK Allity Aged Care partners with PainChek
10/09/18PRICE SENSITIVE
PCK Full Year Statutory Accounts
27/08/18
PCK Preliminary Final Report
27/08/18PRICE SENSITIVE
PCK Appendix 3B
13/08/18
PCK Investor Update
31/07/18PRICE SENSITIVE
PCK Appendix 4C - quarterly
31/07/18PRICE SENSITIVE
PCK National roll out with DSA follows successful pilot
14/06/18PRICE SENSITIVE download Created with Sketch. 289.82KB
PCK New publication confirms accuracy of PainChek(R)
07/06/18PRICE SENSITIVE download Created with Sketch. 297.6KB
PCK Dr Jennifer Abbey joins PainChek Ltd clinical advisory board
04/06/18 download Created with Sketch. 272.49KB
PCK Investor Presentation
17/05/18
PCK PainChek receives FDA regulatory guidance
09/05/18PRICE SENSITIVE
PCK Quarterly Update and Appendix 4C
24/04/18PRICE SENSITIVE
PCK Appendix 3B and Cleansing Notice
13/04/18
PCK Appendix 3B and Cleansing Notice
11/04/18
PCK PainChek DTA training and education video
06/04/18
PCK Appendix 3B and Cleansing Notice
04/04/18
PCK Agreement signed with leading software system provider
27/03/18PRICE SENSITIVE
PCK PainChek Education and Training Presentation
26/03/18
PCK Commentary on Half Year Report
23/02/18
PCK Half Year Report and Financial Statements
23/02/18PRICE SENSITIVE
PCK Quarterly Update and Appendix 4C
30/01/18PRICE SENSITIVE
PCK PainChek App Android version now in beta testing
30/01/18PRICE SENSITIVE
PCK Appendix 3B
29/01/18
PCK New Peer reviewed published study
29/01/18PRICE SENSITIVE
PCK PainChek Head of Business Development ANZ Appointment
22/01/18
PCK Change of Company Name to PainChek Ltd
17/01/18
PCK Certificate of Registration on Change of Name
17/01/18
PCK Results of Meeting
17/01/18
PCK Appendix 3B and Cleansing Notice
21/12/17
PCK Company name change to PainChek Ltd
15/12/17
PCK Notice of General Meeting/Proxy Form
15/12/17
PCK Appendix 3B and Cleansing Notice
13/12/17
PCK 2nd peer-review confirms excellent performance of PainChek
13/12/17PRICE SENSITIVE
PCK Results of Meeting
21/11/17
PCK AGM Presentation
21/11/17
PCK PainChek Childrens App Commercialization Timelines on Track
15/11/17
PCK ePAT and PainChek continue to achieve commercial milestones
08/11/17PRICE SENSITIVE
PCK Quarterly Update and Appendix 4C
31/10/17PRICE SENSITIVE
PCK Appendix 3B and Cleansing Notice
25/10/17
PCK Appendix 3B and Cleansing Notice
20/10/17
PCK Notice of Annual General Meeting/Proxy Form
13/10/17
PCK Appendix 4G and Corporate Governance Statement
12/10/17
PCK Annual Report to shareholders
12/10/17
PCK PainChek trademark and branding supports commercialisation
10/10/17
PCK ePAT accelerates commercialisation at Alzheimers Conference
26/09/17
PCK Cleansing Notice
20/09/17
PCK Appendix 3B
20/09/17
PCK Release of Securities from Escrow
18/09/17
PCK Placement to raise $3.75 million
18/09/17PRICE SENSITIVE
PCK Trading Halt
14/09/17PRICE SENSITIVE
PCK Appendix 3B
08/09/17
PCK Allotment of Deferred Consideration Shares
08/09/17
PCK Core strategic agreement with Dementia Support Australia
07/09/17PRICE SENSITIVE
PCK Full Year Statutory Accounts
29/08/17
PCK Preliminary Final Report
29/08/17PRICE SENSITIVE
PCK ePAT Clinical Study Published in Alzheimer's Disease Journal
15/08/17PRICE SENSITIVE
PCK Response to ASX Price Query
14/08/17PRICE SENSITIVE
PCK Appendix 3B
07/08/17
PCK Quarterly Update and Appendix 4C
31/07/17PRICE SENSITIVE
PCK nViso agrees perpetual global license, takes strategic stake
24/07/17PRICE SENSITIVE
PCK Response to ASX query
24/07/17PRICE SENSITIVE
PCK Appendix 3B
24/07/17
PCK Investor Presentation
19/07/17
PCK ePAT Pain Assessment App Secures Regulatory Clearance
19/07/17PRICE SENSITIVE
PCK New Study Validates Face Recognition App in Pain Detection
04/07/17PRICE SENSITIVE
PCK Investor Presentation
21/06/17
PCK Appendix 3B
11/05/17
PCK Third Quarter Report FY 2016/17
28/04/17
PCK Appendix 4C - quarterly
28/04/17PRICE SENSITIVE
PCK 1st version iOS App Introduced at Pain Society Conference
11/04/17
PCK Appendix 3B
05/04/17
PCK Appointment of Chief Technology Officer
03/04/17
PCK Expiry of listed options
31/03/17
PCK Launch of IBM Case Study
15/03/17PRICE SENSITIVE
PCK Appendix 3B
13/03/17
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
2.8¢ 		Change
0.000(0.00%) 		Mkt cap ! $50.71M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
2 99999 3.0¢
 

Sellers (Offers)

Price($) Vol. No.
2.9¢ 60000 1
View Market Depth
Last trade - 07.10am 22/11/2024 (20 minute delay) ?
PCK (ASX) Chart

Top Stories

Sales growth pushes Lovisa's fortunes (and shares) upwards

Lovisa Holdings Ltd has seen its shares rise more than 2% following a sales update, and on a good day for the consumer discretionary sector
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.